Home > Boards > US Listed > Biotechs > NantKwest (NK)

Just in NK for starters, but heavily invested

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
knoxlube Member Profile
 
Followed By 5
Posts 1,382
Boards Moderated 0
Alias Born 05/08/11
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/9/2019 4:43:47 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/4/2019 6:01:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/23/2019 4:10:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:05:50 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/7/2019 4:02:57 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:09:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/5/2019 5:47:09 PM
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patient... Business Wire - 6/24/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/10/2019 4:04:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:48:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:45:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:42:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:40:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:36:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/7/2019 4:32:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2019 4:07:44 PM
Cheryl Cohen Appointed to NantKwest’s Board of Directors Business Wire - 6/6/2019 4:10:00 PM
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell... Business Wire - 6/4/2019 8:00:00 AM
NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnersh... Business Wire - 6/4/2019 7:45:00 AM
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients Business Wire - 6/3/2019 2:50:00 PM
NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference Business Wire - 6/3/2019 8:00:00 AM
NantKwest, NantCell & NantOmics to Provide Updated Preclinical & Clinical Data in Four Abstracts at Part of the American Soci... Business Wire - 5/31/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 4:10:11 PM
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92®... Business Wire - 5/1/2019 8:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/26/2019 4:13:38 PM
knoxlube   Sunday, 03/10/19 10:09:38 PM
Re: jobilly post# 1164
Post # of 1171 
Just in NK for starters, but heavily invested in one of Dr. PSS other interests at the moment and nothing to do with newspapers. IMO, he's on the right track despite the the slow and painful decline for NK and my beloved cy.. for some time. Believe me, I feel your pain! But I think better days are coming. SOONer or LADR. Whatever that means? ;p

GLTA & NK!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist